ZYME
ZYME
Company information not available. Track real-time insider trading activity, SEC Form 4 filings, and executive stock transactions.
Insider Buys
14
$58.04M
Insider Sales
13
$7.40M
Total Volume
$65.44M
27 transactions
Net Activity
+$50.63M
Net buying
Sentiment Rating
Moderate AccumulationCEO Conviction Index
Liquidating / Profit Taking
Key Drivers
- •Strong buying bias: purchases represent 89% of total transaction value.
- •CEO selling activity detected. Often driven by option expiration or diversification plans.
- •Ultra-high accumulation: total purchase value exceeds $10M.
Score Methodology
The Insider Confidence Score (1-100) measures executive conviction. Starting from a neutral 50, it adjusts based on:
- +15Strong Buy Ratio: Purchases > 70% of volume (or up to -15 for heavy sales).
- +20Cluster Buying: ≥3 unique insiders buying within a 30-day window.
- +15CEO Buying: CEO committing own capital shows high conviction.
- +10CFO Buying: CFO purchasing shares shows financial alignment.
Ecor1 Capital, LLC
Dir, 10%
$58.04M total
Galbraith Kenneth
Chair, CEO
$4.19M total
Moore Paul Andrew
Chief Scientific Officer
$2.07M total
Smith Jeffrey T L
EVP, Chief Medical Officer
$641K total
Schayowitz Adam
EVP, Head of R, D
$358K total
Quick Actions
ZYME has an insider buy conviction of 89%, compared to the Unknown sector buy average of 6%. ZYME ranks #343 in insider activity out of 569 tracked companies in its industry.
Over the last 90 days, corporate insiders at ZYME (ZYME) engaged in a total of 27 transactions reported via SEC Form 4 filings. Among these, 14 were open-market purchases and 13 were sales. The total volume of insider trading reached $65.44M.
The net insider activity for ZYME shows a net buying bias of $50.63M. This activity represents a 89% buy ratio, suggesting that insiders are currently strongly bullish on the company's near-term outlook relative to recent history.
The most notable individual transaction was a Purchase by Ecor1 Capital, LLC (Dir, 10%), who traded 1.25M shares valued at $17.54M on Dec 19, 2024.
Zymeworks Inc. (ZYME) Stock Price, News, Quote & History
Zymeworks Inc. (ZYME) stock price, news, quote and history
Zymeworks management will join fireside chats at two Miami healthcare conferences.
Zymeworks Authorizes Up to $200 Million in Share Repurchases Through 2028
Zymeworks Chief Scientific Officer Andrew Paul Moore Sells $1M After Modest Run-Up
Zymeworks evp Scott Platshon sells $381,535 common stock By Investing.com
FAQs About ZYME Insider Trading
Answers to common questions regarding corporate filings and executive sentiment for ZYME.